Results 1 - 10 of 159

< 1 2 3 ... 15 16 >

• [DOI: 10.1016/j.ejmech.2013.04.017]
  
• [DOI: 10.1021/jm501113m]
  
• Zhao R; Visentin M; Goldman ID. Determinants of the activities of antifolates delivered into cells by folate-receptor-mediated endocytosis., Cancer chemotherapy and pharmacology

  [PubMed: 25847479]
  [DOI: 10.1007/s00280-015-2733-8]
  
• Zhang Q; Shen J; Wang H; Hu J; Yu L; Xie L; Wei J; Liu B; Guan W; Qian X. TS mRNA levels can predict pemetrexed and raltitrexed sensitivity in colorectal cancer., Cancer chemotherapy and pharmacology

  [PubMed: 24281197]
  [DOI: 10.1007/s00280-013-2354-z]
  
• Walling J. From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates., Investigational new drugs

  [PubMed: 16380836]
  [DOI: 10.1007/s10637-005-4541-1]
  
• Tonkinson JL; Marder P; Andis SL; Schultz RM; Gossett LS; Shih C; Mendelsohn LG. Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis., Cancer chemotherapy and pharmacology

  [PubMed: 9118464]
  [DOI: 10.1007/s002800050608]
  
• Successful and Well-Tolerated Second Line Therapy with Cetuximab, Irinotecan, and Raltitrexed in Progressive Liver Disease Due to Metastatic Colon Cancer, Journal of Gastrointestinal Cancer

  [DOI: 10.1007/s12029-009-9060-4]
  
• Second-Line Chemotherapy, Malignant Mesothelioma

  [DOI: 10.1007/0-387-28274-2_40]
  
• Novel chemotherapy agents for colorectal cancer: Oral fluoropyrimidines, oxaliplatin, and raltitrexed, Current Oncology Reports

  [DOI: 10.1007/s11912-999-0028-0]
  
• Preclinical development of Alimta??? (Pemetrexed, LY231514), a multitargeted antifolate, Advances in Targeted Cancer Therapy

  [DOI: 10.1007/3-7643-7414-4_11]